Psychedelics are a class of psychoactive substances that produce profound changes in perception, mood, and thought by activating serotonin receptors in the brain. They include well-known substances like LSD, psilocybin (the active compound in “magic mushrooms”), DMT, and mescaline. Unlike most recreational drugs, psychedelics carry very low risk of physical toxicity or addiction, which is one reason they’ve attracted intense scientific interest as potential treatments for depression and other mental health conditions.
The Three Chemical Families
Classic psychedelics fall into three groups based on their molecular structure: tryptamines, ergolines, and phenethylamines. All three share a key trait: they closely resemble serotonin, a natural brain chemical involved in mood, perception, and cognition.
Tryptamines are the largest family. Psilocybin, DMT, and 5-MeO-DMT all belong here, and their molecular backbone is nearly identical to serotonin itself. Ergolines include LSD, which was originally derived from ergot fungus and then modified through chemical processing. Phenethylamines include mescaline (found in peyote and San Pedro cacti) and a range of synthetic compounds like 2C-B. Each family produces somewhat different subjective effects, but they all work through the same core mechanism in the brain.
How They Work in the Brain
Psychedelics activate a specific type of serotonin receptor called 5-HT2A. When a psychedelic molecule binds to this receptor, it triggers a cascade of signaling inside the neuron that increases excitability, essentially making neurons more responsive and more likely to fire. This heightened neural activity doesn’t happen uniformly across the brain. Instead, it disrupts the usual patterns of communication between brain regions.
One of the most consistent findings from brain imaging studies is that psychedelics reduce activity in something called the default mode network, a set of interconnected brain areas that are most active when you’re resting, daydreaming, or thinking about yourself. This network is thought to maintain your ordinary sense of identity and your habitual patterns of thought. When psychedelics quiet it down, the boundaries between brain networks become less distinct, allowing regions that don’t normally communicate to start exchanging information. This “loosening” of normal brain organization appears to be what produces the characteristic effects: visual distortions, unusual connections between ideas, and shifts in how you experience your own sense of self.
What the Experience Feels Like
Psychedelics alter nearly every dimension of conscious experience: sense perception, emotion, the way time feels, and the felt boundary between yourself and the world around you. Colors often appear more vivid or saturated. Surfaces may seem to breathe, ripple, or display geometric patterns. Sounds can feel textured or emotionally loaded in unfamiliar ways. People frequently report that their attention broadens, as one writer put it, “the spotlight of consciousness becomes a floodlight,” illuminating details and sensations that would normally pass unnoticed.
At higher doses, something more dramatic can happen. The ordinary sense of being a separate “I,” distinct from the world, begins to weaken or dissolve entirely. This is called ego dissolution. People describe it as a loss of the boundary between self and surroundings, sometimes accompanied by a feeling of unity with everything. These experiences can be ecstatic or terrifying depending on the person, the dose, and the setting. Alongside ego dissolution, people often become less psychologically defensive and more able to observe their own thoughts and emotions from a distance, viewing personal material that would normally trigger strong reactions with a kind of detached clarity. This quality was one of the early rationales for using psychedelics in therapy.
The Major Substances
Psilocybin
Psilocybin is the primary psychoactive compound in over 200 species of mushrooms. The body converts it into psilocin, which is the molecule that actually binds to serotonin receptors. Effects typically last four to six hours. In clinical research, the standard dose is 25 mg of synthetic psilocybin, roughly equivalent to a moderate dose of dried mushrooms. Albert Hofmann, the same chemist who discovered LSD’s effects, first isolated psilocybin from mushrooms in 1958, a year after LIFE magazine introduced the English-speaking world to the term “magic mushrooms.”
LSD
LSD (lysergic acid diethylamide) is extraordinarily potent. Its threshold dose is just 15 micrograms, a quantity invisible to the naked eye. Effects last 8 to 12 hours, with residual effects sometimes lingering for a day or two. It was first synthesized in 1938, but its psychoactive properties weren’t discovered until 1943, when Albert Hofmann accidentally absorbed a small amount through his skin. The term “psychedelic,” meaning “mind-revealing,” was coined in 1956 by psychiatrist Humphrey Osmond during a correspondence with writer Aldous Huxley.
DMT
DMT (dimethyltryptamine) is unusual among psychedelics because it occurs naturally in the human body. Research has confirmed that mammalian brain tissue, including human brain tissue, can synthesize DMT, and it has been detected being released from the pineal gland of living rodents. Some researchers have argued it qualifies as a neurotransmitter, since the brain produces it, stores it, releases it, and has mechanisms to break it down. When smoked or injected, DMT produces an intense but short experience lasting roughly 15 to 30 minutes. When consumed orally in ayahuasca, a traditional South American brew that combines DMT-containing plants with an enzyme inhibitor, the experience extends to several hours.
Mescaline
Mescaline is the active compound in peyote and San Pedro cacti and has been used in Indigenous spiritual practices for thousands of years. It belongs to the phenethylamine family, making it structurally different from psilocybin and DMT. Effects last roughly 10 to 12 hours and tend to be described as producing a warm, grounded quality compared to the other classic psychedelics.
What Psychedelics Are Not
MDMA (sometimes called ecstasy or molly) is frequently grouped with psychedelics in casual conversation, but pharmacologists classify it separately as an “entactogen,” a term meaning “touching within.” While psychedelics work primarily by binding to serotonin receptors, MDMA works by flooding the brain with serotonin, dopamine, and norepinephrine. It produces feelings of emotional closeness and empathy rather than the perceptual distortions and ego dissolution characteristic of classic psychedelics. Ketamine, another substance sometimes called psychedelic, operates on an entirely different receptor system. These distinctions matter because the therapeutic applications, risks, and subjective effects differ significantly between these categories.
Safety Profile
Classic psychedelics are physiologically non-toxic, meaning they do not damage organ systems even at very high doses. They carry the lowest rate of dependence of any category of psychoactive drug studied. In one large representative survey, only 4.9% of people who had used psychedelics ever qualified for a dependence diagnosis, lower than any other drug class analyzed, including cannabis and alcohol. Systematic comparisons consistently rate psychedelics as less harmful to both the individual user and society than alcohol and nearly all other controlled substances.
The real risks are psychological rather than physical. A difficult experience, sometimes called a “bad trip,” can involve intense fear, paranoia, or confusion. In rare cases, psychedelics can trigger lasting psychological distress, particularly in people with a personal or family history of psychotic disorders like schizophrenia. The context in which someone takes a psychedelic, often described as “set and setting” (mindset and physical environment), has a powerful influence on whether the experience is positive or negative.
Clinical Research and Legal Status
Between the late 1940s and mid-1960s, psychedelics were the subject of intensive psychiatric research. Over a thousand clinical papers were published, and LSD in particular was explored as a tool for treating alcoholism, anxiety, and depression. That era ended abruptly when psychedelics became associated with the counterculture movement. By 1966, prohibition began in the United States, and research was effectively halted for decades.
The current wave of research, sometimes called the “psychedelic renaissance,” has produced striking results. The FDA granted psilocybin breakthrough therapy designation in 2018 for treatment-resistant depression and again in 2019 for major depressive disorder, a label reserved for therapies that show substantial improvement over existing treatments. Clinical trials typically involve one to three supervised dosing sessions alongside psychotherapy, not ongoing daily use like a conventional antidepressant.
Despite this clinical momentum, psilocybin, LSD, and DMT remain Schedule I controlled substances in the United States and are banned in most countries. A handful of jurisdictions have moved to decriminalize or create regulated access. Oregon became the first U.S. state to create a legal framework for supervised psilocybin therapy, and several cities have deprioritized enforcement of psychedelic possession laws. Australia approved psilocybin for treatment-resistant depression in supervised clinical settings in 2023. The legal landscape is shifting rapidly, but for now, possession and use remain illegal in most of the world.